Device Trial Radar · NCT00967746
An Explorative Trial to Explore the Safety, Acceptability and Vaginal Bleeding Pattern of Three Etonogestrel-releasing Medicated Intrauterine Systems (Study P06060)
Last checked: Nov 20, 2026Latest source record: Apr 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
84
Actual
Start
Nov 2009
Primary completion
Nov 2010
Study completion Jul 2011
Sponsor
- Lead sponsor
- Organon and CoNot on our public-company list
- Sponsor type
- Industry
- First posted
- Aug 28, 2009
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Prevention
- Who can join
- Female only, from 18 years, up to 40 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a phase 2, randomized, active-controlled, parallel-group, multicenter, single-blind trial of three different doses of etonogestrel releasing medicated intrauterine systems (ENG-MIUS) in healthy parous women in need for contraception. The primary trial objective is to explore safety and acceptability of three doses of an ENG-releasing medicated intrauterine system (ENG-MIUS) as compared to Multiload-cu 375®.
Conditions
- Contraception
Interventions
Etonogestrel-releasing IUSDrug
Low dose; treatment duration of 6 months with a possible extension to 12 months
Etonogestrel-releasing IUSDrug
Intermediate dose; treatment duration of 6 months with a possible extension to 12 months
Etonogestrel-releasing IUSDrug
High dose; treatment duration of 6 months with a possible extension to 12 months
Multiload-cu 375®Device
Duration of 6 months with a possible extension to 12 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary efficacy outcome for the trial is insertion and removal characteristics, adverse event reporting and subject's satisfaction with the ENG-MIUSTime frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Dinox GmbH
Berlin, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.